Sign in Subscribe
Cancer

Revolutionizing Cancer Treatment with EASYGEN Initiative

Strategic Insights

— 1 min read

The Euro 8 million European initiative, led by Bar-Ilan University, aims to decentralize the production of CAR-T cell therapy, a cutting-edge treatment for cancer, by developing a fully automated system that allows hospitals to manufacture the therapy on-site in just 24 hours. This project, called EASYGEN, will bring advanced gene therapy closer to where patients are treated, making it more accessible and reducing costs.

Key Takeaways:

  • The EASYGEN project, funded by the EU-backed Innovative Health Initiative (IHI), is a five-year initiative aimed at developing a fully automated system for producing CAR-T therapies on-site in hospitals.
  • The project brings together 18 partners from 8 countries, including leading hospitals, research institutes, and biotech companies, to collaboratively deliver innovative, personalized therapies to patients.
  • Prof. Ayal Hendel's lab at Bar-Ilan University's Goodman Faculty of Life Sciences will focus on evaluating the precision and safety of CRISPR-based gene editing, a core part of the therapy.
  • The EASYGEN project aims to decentralize the production of CAR-T therapies, making them more broadly accessible, especially in non-academic clinical environments.
  • The project has the potential to make CAR-T therapies more affordable, faster to produce, and more reliable, transforming cancer care in hospitals.
  • Bar-Ilan University is a key contributor to the project, highlighting its growing role in high-impact, translational biomedical research.

Statistics:

  • The EASYGEN project is funded by Euro 8 million from the EU-backed Innovative Health Initiative (IHI).
  • The project aims to develop a fully automated system for producing CAR-T therapies on-site in hospitals in just 24 hours.
  • The project brings together 18 partners from 8 countries, including leading hospitals, research institutes, and biotech companies.
  • CAR-T cell therapy is still only available to a small number of patients due to the slow, expensive, and centralized production process.

Sources:

  • "Bar-Ilan University joins major new Euro 8 million European initiative to revolutionize how personalized cancer treatments like CAR-T cell therapy are delivered in hospitals." (VerticalNews, 2025 Sep 14)
  • "EASYGEN: Easy workflow integration for gene therapy" (European initiative, no date)
  • "Fresenius SE & Co. KGaA" (press release, no date)
  • "The Institute for Genome Engineering at Bar-Ilan University" (press release, no date)

Read more